tients with type 2 diabetes (DURATION-3):an open-label randomised trial. Lancet 2010;375:2234 –2243 18. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions inHbA(1c) over 1 year in drug-naïve patientswith type 2 diabetes. Diabet Med 2007;24: 955–961 19. Johansen K. Ef ﬁcacy of metformin in the treatment of NIDDM: meta-analysis. Di-abetes Care 1999;22:33 –37 20. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combinationwith metformin as initial therapy improves glycemic control in patients with type 2 di- abetes compared with either monotherapy:a randomized controlled trial. DiabetesObes Metab 2009;11:611 –622 21. Liutkus J, Rosas Guzman J, Norwood P, et al. A placebo-controlled trial of exenatidetwice-daily added to thiazolidinedionesalone or in combination with metfor- min. Diabetes Obes Metab 2010;12: 1058 –106522. Schweizer A, Dejager S, Bosi E. Compar-